期刊
EUROPEAN JOURNAL OF IMMUNOLOGY
卷 40, 期 10, 页码 2791-2796出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/eji.201040511
关键词
CD205/DEC-205; DCIR2; DC; LcrV; Yersinia pestis
类别
资金
- National Institutes of Health [5 U54 AI057158, AI13013]
- NBC
- NIH/NIAID [1R21AI082331-01]
- Korea Government (MEST) [2010-0002810]
- German Research Foundation [DU548/1-1, DU548/2-1]
- National Research Foundation of Korea [2010-0002810] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
To help design needed new vaccines for pneumonic plague, we targeted the Yersinia pestis LcrV protein directly to CD8 alpha(+) DEC-205(+) or CD8 alpha(-) DCIR2(+) DC along with a clinically feasible adjuvant, poly IC By studying Y. pestis in mice, we could evaluate the capacity of this targeting approach to protect against a human pathogen. The DEC-targeted LcrV induced polarized Th1 immunity, whereas DCIR2-targeted LcrV induced fewer CD4(+) T cells secreting IFN-gamma, but higher IL-4, IL-5, IL-10, and IL-13 production. DCIR-2 targeting elicited higher anti-LcrV Ab titers than DEC targeting, which were comparable to a protein vaccine given in alhydrogel adjuvant, but the latter did not induce detectable T-cell immunity. When DEC- and DCIR2-targeted and F1-V+ alhydrogel-vaccinated mice were challenged 6 wk after vaccination with the virulent CO92 Y. pestis, the protection level and Ab titers induced by DCIR2 targeting were similar to those induced by F1-V protein with alhydrogel vaccination. Therefore, LcrV targeting to DC elicits combined humoral and cellular immunity, and for the first time with this approach, also induces protection in a mouse model for a human pathogen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据